🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SANUWAVE Health, Inc. SNWV R2KPHARMA

Healthcare · Medical Devices · United States
https://sanuwave.com
Company Profile ↓
$4.38
-89.02% 1Y
Mkt Cap$37.66M
P/E4.56
P/B27.48
52W High$45.00
52W Low$4.38
Book Value$0.21
EPS (TTM)$0.96

Company Overview

SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 25.4%.

Steady Revenue Expansion

Revenue has grown at a 31.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 4.6, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 37.2%.

Recent Developments

  • Dec 2025 Revenue of $44.05M (+36.3% YoY); net profit $11.81M.
  • Trailing 12 Months Year-on-year growth — revenue +3.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 31.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:31.45%
1 Year:3.10%

Stock Price Performance

1 Year:-89.02%
6 Months:-81.10%
3 Months:-70.33%
1 Month:-27.00%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$4.38 $45.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)28.43 · Oversold
Price Performance
1M-27.00%
3M-70.33%
6M-81.10%
1Y-89.02%
Valuation vs Sector

P/E of 4.56 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 25.4%.
  • Excellent profit margin of 37.2%.
  • Compounding revenue at 31.4% over 5 years.

CONS

  • Trading 90.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
4.56
Industry PE
25.17
Forward P/E
-438.00
PEG Ratio
-
Book Value
$0.21
Price to Book
27.48
P/S
1.14
EV/EBITDA
10.77
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
31.45%
Profit 5Y
-
Revenue (YoY)
3.10%
Earnings (YoY)
-

Profitability & Returns

ROCE
25.36%
ROE
-
ROA
8.81%
Profit Margin
37.20%
Op Margin
-11.68%
Gross Margin
76.74%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$0.96

Balance Sheet & Liquidity

Debt/Equity
12.06
Quick Ratio
0.92
Current Ratio
1.31
Debt
$22.16M
Total Assets
$36.60M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.30%
Chg in Prom Hold
-0.00%
FII / Inst Holding
37.34%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$37.66M
Total Revenue (TTM)
$44.34M
EBITDA
$5.85M
Free Cash Flow
$-5.50M
Operating Cash Flow
$5.79M
Shares Outstanding
8.60M
Gross Margin
76.74%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SNWV SANUWAVE Health, Inc. R2KPHARMA 4.38 4.56 $37.66M 0.00% 25.36% - 31.45% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -------------------197.64K149.00K83.00K1.37M1.86M2.63M3.73M2.85M3.54M3.92M3.49M4.41M4.82M5.68M7.08M9.29M9.29M10.15M11.42M--
Gross Profit 136.83K118.95K126.76K174.72K159.41K151.63K164.20K104.85K196.14K125.42K156.97K--99.90K178.81K286.57K412.19K84.11K131.09K74.72K19.00K4.00K765.00K1.06M1.86M2.17M2.31M2.79M3.01M2.51M3.47M3.54M4.20M5.24M7.07M7.38M7.85M8.74M7.43M7.42M
Operating Income -1.73M-1.89M-2.02M-1.61M-1.41M-1.13M-1.01M-1.32M-689.47K-1.02M-833.61K-620.64K-1.31M-647.78K-1.12M-2.12M-2.67M-1.86M-2.02M-2.39M-2.80M-3.27M-6.37M-4.39M-4.05M-3.33M-1.96M-3.05M-2.48M-1.98M931.00K-531.00K-1.29M1.65M1.48M601.00K1.44M903.00K-1.12M-280.00K
Net Income -818.33K-4.44M-2.56M-1.69M-1.49M-1.16M-1.52M-1.03M-1.72M-1.12M-1.14M-493.53K-1.42M-851.33K-5.86M-2.89M-825.14K-2.20M-2.73M-2.75M-3.00M-3.63M-12.64M-4.94M-8.62M-4.25M-5.10M1.64M-1.14M-13.08M-7.26M-23.70M-4.80M6.19M-21.16M-6.12M551.00K9.69M-1.44M-682.00K
Diluted EPS -0.04-0.14-------------------0.01-0.01-0.03-0.01-0.02-0.01-0.010.000.00-0.02-0.01-9.950.000.00-6.65-0.72-0.040.39-0.17-0.08
R&D Expense 624.53K775.72K764.85K1.01M708.30K634.62K456.79K569.13K309.95K476.17K266.47K260.34K437.91K266.84K238.48K328.75K622.15K261.00K307.27K299.90K287.00K265.00K432.00K354.00K272.00K297.00K166.00K171.00K157.00K131.00K139.00K165.00K163.00K195.00K161.00K208.00K194.00K345.00K660.00K628.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 728.45K802.57K769.22K800.03K847.37K965.50K1.38M738.53K1.85M1.03M3.63M11.38M15.51M19.25M32.33M44.05M
Gross Profit 478.12K540.68K548.96K610.24K627.39K680.54K-496.56K1.16M489.81K2.90M8.02M12.41M14.36M24.55M33.97M
Operating Income -11.81M-8.81M-6.06M-5.98M-5.96M-4.44M-3.32M-3.82M-7.18M-8.79M-25.20M-14.14M-8.95M-540.00K3.85M4.95M
Net Income -14.92M-10.24M-6.40M-11.30M-5.97M-4.81M-6.44M-5.54M-11.63M-10.43M-30.94M-27.26M-10.29M-25.81M-33.08M11.81M
Diluted EPS -1.15-0.52-0.30-------0.05-0.08-0.05-0.02-12.19-7.410.41
R&D Expense 3.88M2.73M1.76M2.30M3.00M2.17M1.13M1.29M981.65K1.18M1.25M1.10M567.00K579.00K673.00K1.35M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Dec 2023Jan 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Total Assets -3.03M6.17M1.85M1.59M4.67M958.36K1.00M1.28M1.18M3.38M23.03M18.62M17.01M17.84M18.78M19.87M22.42M-30.12M---37.34M
Total Equity --10.52M-1.54M-6.52M-6.13M-1.55M-5.88M-6.91M-9.88M-15.36M-10.06M-13.72M-38.96M-38.07M-35.53M-35.31M-41.01M-44.55M-44.55M-15.79M-20.81M-18.80M-7.59M1.62M
Cash & Equivalents 1.79M417.46K3.91M70.33K182.31K3.55M152.93K133.57K730.18K364.55K1.76M2.44M619.00K313.00K1.48M1.11M1.15M1.80M-10.24M---11.96M
Long Term Debt ---5.37M---5.37M---143.00K875.00K----------16.14M
Total Liabilities -13.55M7.70M8.37M7.72M6.22M6.84M7.92M11.16M16.53M13.45M36.74M57.58M55.08M53.38M54.09M60.88M65.59M66.96M45.91M51.67M51.84M43.19M35.72M
Current Liabilities -8.17M2.32M2.99M2.34M6.22M1.49M7.92M11.16M16.49M12.42M36.17M56.26M53.91M52.25M53.59M60.22M64.75M-45.42M50.78M50.42M23.98M17.85M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.87M-8.83M-4.29M-3.92M-6.68M-3.47M-3.20M-1.53M-3.62M-6.41M-12.72M--17.17M-4.54M2.46M3.88M
Investing Cash Flow 7.00K-42.30K-2.01K7.50K-8.86K100.00K-8.77K0-42.89K-53.94K-20.05M-332.00K21.00K-490.00K3.43M
Financing Cash Flow 4.50M12.37M450.42K4.04M10.07M-3.21M2.12M3.32M7.86M33.45M-17.38M5.21M6.35M-5.59M
Capital Expenditure --42.30K-2.01K--8.86K--10.36K-0-42.89K-53.94K-53.00K-529.00K---490.00K-1.94M
Free Cash Flow --8.87M-4.29M--6.69M--3.21M-1.53M-3.66M-6.46M-12.77M--17.17M-4.54M1.97M1.93M
Net Change in Cash ------------547.00K694.00K8.32M1.72M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 65.6%67.4%71.4%76.3%74.0%70.5%-67.2%62.5%47.6%79.8%70.5%80.0%74.6%75.9%77.1%
Operating Margin % -1,620.9%-1,097.6%-788.1%-747.0%-703.8%-459.6%-241.0%-517.8%-388.1%-854.9%-694.6%-124.2%-57.7%-2.8%11.9%11.2%
Net Margin % -2,048.5%-1,275.7%-832.2%-1,412.4%-705.0%-498.2%-467.9%-749.9%-628.7%-1,013.9%-852.7%-239.5%-66.4%-134.0%-102.3%26.8%
ROE % 141.9%666.4%98.2%184.4%385.1%81.8%93.2%56.0%75.7%103.6%225.5%70.0%25.1%57.9%209.5%729.6%
ROCE % 229.6%-229.1%530.7%791.4%384.4%837.8%48.0%38.7%46.9%97.4%191.7%37.6%22.2%1.3%-25.1%25.4%

Shareholding Pattern

Insiders
1.30%
Institutions
37.34%
Public Float
37.84%

Top Institutional Holders

#Holder% HeldSharesValue
1 Solas Capital Management, LLC 7.15% 610.97K $2.86M
2 AWM Investment Company, Inc. 5.32% 454.55K $2.13M
3 Praetorian PR LLC 4.62% 395.00K $1.85M
4 Vanguard Capital Management LLC 4.13% 352.76K $1.65M
5 Opaleye Management Inc. 3.58% 306.14K $1.43M
6 UBS Group AG 3.00% 256.79K $1.20M
7 Blackrock Inc. 1.87% 159.87K $747.38K
8 Geode Capital Management, LLC 1.01% 86.10K $402.51K
9 Citadel Advisors Llc 0.70% 59.47K $278.04K
10 Vanguard Fiduciary Trust Co 0.50% 43.10K $201.48K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SNWV

Google News Mon, 27 Apr 2026

How The SANUWAVE Health (SNWV) Story Is Shifting After The Latest Price Target Reset - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOa3h3X08xLWRWZi0zRnVPd1J2alJhUF9LNVB6bFVibTBvWFBQTGRVUHVSQnVfRzJhX3RhcjNORDhVa1ZncVFtTlItSWlMQkdKeGhJM1pSTnVxWXN1T1Z4NU1BOEJXS3NPNUVqMmdXTjUzbjRuTHZMVG1kc0E3blNoTWRZRDJuU29NVmpFMT…

Google News hu, 28 May 2026

SNWV - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1IVVRQYklsd0I2QmxzZjhWdTdiTHNTYUY4MHR2THVZREl0czVKMjFWa1I4LUJYNzNyZENtRUlEU1NPNHNybUE?oc=5" target="_blank">SNWV</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News ue, 16 Jun 2026

$SNWV stock is down 40% today. Here's what we see in our data. - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxON3AyV1ZxZWNqM2pyMUFrdVhWeXhwUXdaR0t0cFBaM002dWdMTTRqVTJFNlhMQ3hzdHY4bUoySFdnV2NydTJZSTJ0TzR5eXRiOHM5Z3FwZjVGR0I1dzExVnI5VXlKd1FCWHAwNy1Na0NSMVZHYk92Qmppc2RaX0YwVlVKdFM1emZSSkdEYn…

Google News hu, 21 May 2026

Shareholders Shouldn’t Be Too Comfortable With SANUWAVE Health's (NASDAQ:SNWV) Strong Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNR1dFZEZjaDB5MnltcGEydG5HMU14VGdqUTZFMTNmQmFCZEdrdGtxellSbW1pNzZZNVFiLTFnUHVjR1NoSUhJaU9Zd2x1bEVPODI0RWI1STBWTzJfVFNrdHRnRmZrR3BYU3dfQ3BRQlpGdW50VktHb2loN0JWOXBOaGt6S3VOa0UzTk5NTj…

Google News hu, 16 Jul 2026

Market Movers | Winners: CPHI, SOBR, ELVA | Losers: ILLR, SNTI, SNWV - Trefis

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNX3BrWlZmdGNpVHJWbEtYUDc0QmVsSWRGQVVoQmlPZksxSDgxRm50bkpxOG94di0xTXBqUjZ2dndzZGlEN0hTU3RIaDVoTTZsMnluR1QtaWZyNHhOdUhQVmc4OVo3V0tPeGFlTVJyd3JGdEdZeVZUbjh1bnlTbmZsTWZiMTZVaXpLZ3RhUW…

Google News Wed, 26 Aug 2026

SANUWAVE Health, Inc. Common Stock (NASDAQ: SNWV) Stock Price, News & Analysis - kalkine.ca

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE4yRndDdkhMMW5QalQ1dms4R2pIcGs3ZERoOENQUTVFRDZWTTJiOHlZaTdBblp3X0xfQWpYczJhamZrb2RiRm9sN3F0a0RkeVUt?oc=5" target="_blank">SANUWAVE Health, Inc. Common Stock (NASDAQ: SNWV) Stock Pri…

SNWV — Frequently Asked Questions

What is the current share price of SANUWAVE Health, Inc. (SNWV)?

As of 2026-09-07 16:24 PDT, SANUWAVE Health, Inc. (SNWV) trades at $4.38 on NasdaqGM. Its 52-week range is $4.38 to $45.00.

What is the market capitalisation of SNWV?

SANUWAVE Health, Inc. (SNWV) has a market capitalisation of $37.66M on NasdaqGM.

What is the P/E ratio of SNWV?

SNWV trades at a trailing price-to-earnings (P/E) ratio of 4.56. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 27.48.

Is SNWV a good stock to buy?

This page provides a data-driven analysis of SANUWAVE Health, Inc. (SNWV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space